
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Anteris Technologies Global Corp. Common Stock (AVR)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: AVR (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $16.5
1 Year Target Price $16.5
3 | Strong Buy |
1 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -29.91% | Avg. Invested days 5 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 287.16M USD | Price to earnings Ratio - | 1Y Target Price 16.5 |
Price to earnings Ratio - | 1Y Target Price 16.5 | ||
Volume (30-day avg) 4 | Beta 0.74 | 52 Weeks Range 2.34 - 8.79 | Updated Date 05/15/2025 |
52 Weeks Range 2.34 - 8.79 | Updated Date 05/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.98 |
Earnings Date
Report Date 2025-08-14 | When After Market | Estimate -0.53 | Actual -0.5777 |
Profitability
Profit Margin - | Operating Margin (TTM) -2678.44% |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) -840.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 279733221 | Price to Sales(TTM) 101.59 |
Enterprise Value 279733221 | Price to Sales(TTM) 101.59 | ||
Enterprise Value to Revenue 103.18 | Enterprise Value to EBITDA - | Shares Outstanding 35939800 | Shares Floating 17135301 |
Shares Outstanding 35939800 | Shares Floating 17135301 | ||
Percent Insiders 7.63 | Percent Institutions 45.17 |
Upturn AI SWOT
Anteris Technologies Global Corp. Common Stock
Company Overview
History and Background
Anteris Technologies (ANTE) is a structural heart company focused on developing DurAVRu2122, a transcatheter heart valve (THV) addressing unmet needs in aortic stenosis. Founded in Australia, it has shifted its focus to the US market.
Core Business Areas
- Structural Heart Solutions: Development and commercialization of DurAVRu2122, a novel transcatheter aortic valve replacement (TAVR) device.
Leadership and Structure
The company is led by a management team focused on innovation and has a board of directors with expertise in medical devices. Details on specific individuals can be found in their annual reports and investor presentations.
Top Products and Market Share
Key Offerings
- DurAVRu2122: DurAVRu2122 is a transcatheter heart valve (THV) designed to treat aortic stenosis. It aims to improve upon existing TAVR technologies with a unique single-piece design mimicking a natural valve. Competitors include Edwards Lifesciences (EW) and Medtronic (MDT). Market share is currently zero as the product is still in clinical trials and not yet commercially available. Potential market share depends on clinical trial outcomes and regulatory approvals.
Market Dynamics
Industry Overview
The structural heart market, particularly the TAVR segment, is experiencing significant growth due to an aging population and increasing adoption of minimally invasive procedures. Key players are constantly innovating to improve device performance and expand indications.
Positioning
Anteris Technologies aims to differentiate itself with DurAVRu2122, which is designed to offer improved hemodynamics and durability compared to existing TAVR devices. Success depends on positive clinical trial results and regulatory approvals.
Total Addressable Market (TAM)
The global TAVR market is projected to reach billions of USD annually. Anteris's position relative to this TAM depends on the successful commercialization of DurAVRu2122. Failure to get market approval could mean zero market share.
Upturn SWOT Analysis
Strengths
- Novel DurAVRu2122 technology with potential for improved performance
- Focus on unmet needs in aortic stenosis treatment
- Experienced management team
- Intellectual property protection for DurAVRu2122
Weaknesses
- No currently approved products
- Reliance on successful clinical trial outcomes
- High R&D expenses
- Limited financial resources compared to larger competitors
- Negative Earnings history.
Opportunities
- Growing TAVR market
- Potential for expanded indications for DurAVRu2122
- Strategic partnerships
- Acquisition by a larger medical device company
Threats
- Competition from established players (EW, MDT)
- Regulatory hurdles and delays
- Unsuccessful clinical trials
- Technological advancements by competitors
- Patent infringement litigation
Competitors and Market Share
Key Competitors
- EW
- MDT
- BSX
Competitive Landscape
Anteris Technologies faces stiff competition from established players with extensive resources and existing TAVR products. Its success hinges on demonstrating superior clinical outcomes with DurAVRu2122.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by preclinical and clinical development activities, rather than revenue growth.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization of DurAVRu2122. Analyst estimates vary depending on the perceived likelihood of success.
Recent Initiatives: Recent initiatives include enrolling patients in clinical trials and presenting clinical data at medical conferences.
Summary
Anteris Technologies is a high-risk, high-reward investment. Its future relies heavily on the success of DurAVRu2122 and positive clinical trial results. The company needs to carefully manage its cash burn rate and navigate the regulatory landscape effectively. While there are many threats, the company has the ability to disrupt a growing market, if it can successfully commercialize DurAVR.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q)
- Company Website
- Investor Presentations
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investing in Anteris Technologies carries significant risk due to its development-stage nature.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Anteris Technologies Global Corp. Common Stock
Exchange NASDAQ | Headquaters Toowong, QLD, Australia | ||
IPO Launch date 2024-12-13 | Vice Chairman & CEO Mr. Wayne Geoffrey Paterson | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 136 | Website https://anteristech.com |
Full time employees 136 | Website https://anteristech.com |
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.